BMS specializes in the development and manufacturing of biomedical textile implants, while MPC focuses on the development and manufacturing of precise polymer components.
The combined company, which will operate as Confluent Medical Technologies, offers complementary, best-of-class technologies to provide customers with a single-source solution for high-quality, cost-competitive medical device contract manufacturing, testing, and design services.
“The acquisition of Biomedical Structures and Modified Polymer Components is another step in our strategy of expanding our portfolio of medical technologies,” said Dean Schauer, president and CEO of Confluent Medical. “The combination of Confluent Medical with Biomedical Structures and Modified Polymer Components allows us to provide our customers with a consolidated organization for the full-scale design, testing, and manufacturing of their life-saving devices. We are thrilled to be able to provide our customers with an expanded suite of industry-leading technologies as well as high-quality, cost-competitive, best-in-class manufacturing.”
BMS specializes in the advanced design, development, and manufacture of biomedical textiles for device manufacturers in the orthopedic, cardiovascular, general surgery, and tissue-engineering markets. With specialized expertise in biopolymer fabrication techniques, BMS enables implantable devices and other medical applications. The company provides a full line of services from concept design to full-scale production, supply chain management, and post-manufacturing sterilization and packaging.
MPC specializes in the design, development, and manufacture of highly precise polymer components and assemblies. MPC’s extensive production capabilities enable it to perform secondary operations for all types of polymer tubing, including complex multi-lumen extrusions, to create ramps, tips, and almost any imaginable feature.
Confluent Medical, BMS, and MPC were all portfolio companies of Ampersand Capital Partners. Ampersand will be a significant investor in the integrated company, Confluent Medical Technologies.
Confluent Medical’s expanded portfolio of services includes:
•Medical textile design, development, and contract manufacturing
•Specializing in cardiovascular and orthopedic implants
Precision Polymer Components
•Precise polymer component design and production
•Specializing in vascular delivery systems
Nitinol Components and Material
•Nitinol component contract manufacturing
•Nitinol device design and testing services
Balloon Expandable Stents and Balloon Catheters
•Balloon expandable stent and balloon catheter production
•Balloon manufacturing equipment
•High-quality and cost-competitive extrusion, including Tri-Layer
•Guidewire contract manufacturing
•Specializing in hydrophilic-coated guidewires
Confluent Medical Technologies is a contract manufacturer of Nitinol-based and balloon catheter medical devices. With manufacturing facilities in Fremont, Calif.; Laguna Niguel, Calif.; and San Jose, Costa Rica; Confluent Medical Technologies has a 20-year track record of partnering with the medical device community and delivering medical devices.
Biomedical Structures provides advanced design services, development, and manufacturing of medical textiles for device manufacturers in the orthopedic, cardiovascular, general surgery, and tissue-engineering markets. With manufacturing facilities in Warwick, R.I., and specialized expertise in polymer technologies and medical-grade manufacturing techniques, BMS partners with some of the world’s largest device makers.
Modified Polymer Components specializes in the design, development, and manufacture of highly precise polymer components for medical device companies. MPC specializes in providing the components and assemblies for vascular delivery systems at its Sunnyvale, Calif., development and manufacturing facility.
Ampersand Capital Partners is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships.